



NDA 021835/S-006

SUPPLEMENT APPROVAL

Galderma Laboratories, LP
Attention: Richard Almond
Senior Manager, Regulatory Affairs
14501 N. Freeway
Fort Worth, TX 76177

Dear Mr. Almond:

Please refer to your Supplemental New Drug Application (sNDA) dated and received March 9, 2012, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Clobex[®] (clobetasol propionate) Spray, 0.05%.

We acknowledge receipt of your amendments dated August 22, and September 5, 2012.

This "Prior Approval" supplemental new drug application, submitted as a CBE-30, provides for revisions to the patient information section of the package insert, carton labels, and clarify instructions for the 360° swivel pump.

Additionally, the carton and container labels were revised according to current standards and descriptor information was added to the following sections of the package insert: Dosage Forms and Strengths, Description, and How Supplied/Storage and Handling.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, carton and container labels), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(1)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and container labels that are identical to the enclosed carton and immediate container labels **and** carton and immediate container labels submitted on September 5, 2012 as soon as they are available, but no more than 30 days after they are printed.

Please submit these labels electronically according to the guidance for industry titled “Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008).” Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Product Correspondence – Final Printed Carton and Container Labels for approved NDA 021835/S-006.**” Approval of this submission by FDA is not required before the labeling is used.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Dawn Williams, Regulatory Project Manager, at (301) 796-5376.

Sincerely,

{See appended electronic signature page}

Stanka Kukich, MD
Deputy Director
Division of Dermatology and Dental Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURES:

Content of Labeling
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

STANKA KUKICH
09/07/2012